Results 221 to 230 of about 14,786 (290)

Proteolysis-targeting chimeras in cancer therapy: Targeted protein degradation for next-generation treatment. [PDF]

Cancer
Anaya YA, Barragan M, Bracho RP, Shaham SH, Bandyopadhyay D, George E, Nguyen D, Tripathi MK.   +7 more
europepmc   +1 more source

Targeting the Spliceosomal Protein USP39 Through Allosteric Ligands and PROTAC-Induced Degradation. [PDF]

Angew Chem Int Ed Engl
Schäfer D, Prieto-Garcia C, Wang J, Heinz M, Matkovic V, Kielkowski P, Hasselbeck S, Shah VJ, Knapp S, Hummer G, Dikic I, Cheng X.   +11 more
europepmc   +1 more source

Therapeutic advances in acute myeloid leukemia: from LSD1 blockade to PROTAC-based strategies. [PDF]

Ann Med Surg (Lond)
Khan SA, Qamar MA, Feroze MT.
europepmc   +1 more source

Targeting β-catenin: PROTACs and precision degraders for Wnt-driven cancers. [PDF]

Front Oncol
Trapani J, Caroland KP, Ahmed Y, Robbins DJ, Weiss VL, Lee E.   +5 more
europepmc   +1 more source

Computational Modeling of PROTAC Ternary Complexes as Ensembles Using SILCS-xTAC. [PDF]

J Chem Inf Model
Nordquist EB, Zhao M, Yu W, MacKerell AD.   +3 more
europepmc   +1 more source

Antioxidant Natural Compounds Integrated with Targeted Protein Degradation: A Multi-Modal Strategy for Alzheimer's Disease Therapy. [PDF]

Antioxidants (Basel)
Singh DD, Yadav DK, Shin D.
europepmc   +1 more source

Development of Trivalent PROTACs Based on BRD4-targeting PROTACs

Development of Trivalent PROTACs Based on BRD4-targeting PROTACs
openaire  

Frontiers in PROTACs [PDF]

Drug Discovery Today, 2021
Targeting protein-protein interactions (PPI) is a key focus in the development of new and emerging small-molecule therapeutics. Shallow interacting surfaces can render PPI targeting notoriously difficult. This leaves many therapeutically captivating targets 'undruggable'.
Gregory R Hughes, Ashley P Dudey, Andrew Chantry   +2 more
exaly   +4 more sources